Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.5.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash Flows from Operating Activities:    
Net Loss $ (49,988) $ (38,808)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation expense 240 17
Noncash interest expense 0 167
Amortization of debt discount 586 143
Amortization of product revenue license fee 50 0
Stock-based compensation expense 8,792 11,896
Issuance of subsidiaries' common shares for license expenses 48 0
Financing fees on Helocyte Convertible Note, at fair value 491 0
Change in fair value of investments 1,800 65
Change in fair value of derivative liabilities 105 0
Change in fair value of subsidiary convertible note 13 0
Research and development-licenses acquired, expense 3,095 9,923
Unrealized (gain) loss on marketable securities 0 (11)
Changes in operating assets and liabilities:    
Accounts receivable (118) 0
Inventory (123) 0
Other receivables - related party (1,389) (69)
Prepaid expenses and other current assets (797) (325)
Accounts payable and accrued expenses 5,364 4,375
Interest payable 41 (2)
Other long-term liabilities 3,948 (687)
Net cash used in operating activities (27,842) (13,316)
Cash Flows from Investing Activities:    
Net cash acquired in acquisition of National 4,626 0
Purchase of marketable securities, at fair value 0 (19,938)
Purchase of research and development licenses (3,095) (9,923)
Purchase of property and equipment (5,756) (94)
Purchase of license (350) (1,250)
Security deposits funded (5) 0
Investment in Origo Acquisition Corp. (175) (130)
Net cash used in investing activities (4,755) (31,335)
Cash Flows from Financing Activities:    
Proceeds from exercise of stock options 0 216
Proceeds from issuance of common stock under ESPP 81 26
Proceeds from subsidiary's offering 13,016 12,575
Payment of costs related to subsidiary's public offering (1,364) (1,507)
Proceeds from at-the-market offering 434 0
Payment of cost related to at-the-market offering (49) 0
Payment of NSC note (2,792) 0
Proceeds from NSC note 0 10,000
Payment of debt issuance costs associated with NSC Note 0 (855)
Proceeds from Helocyte Convertible Note 3,018 0
Payment of debt issuance costs associated with Helocyte Convertible Note (392) 0
Proceeds from Opus Credit Facility 5,000 0
Proceeds from IDB Note 920 0
Transfer of restricted cash (920) 0
Net cash provided by financing activities 16,952 20,455
Net decrease in cash and cash equivalents (15,645) (24,196)
Cash and cash equivalents at beginning of period 98,182 49,759
Cash and cash equivalents at end of period 82,537 25,563
Supplemental disclosure of cash flow information:    
Cash paid for interest 238 80
Supplemental disclosure of non-cash financing and investing activities:    
Issuance of restricted stock 2 1
Issuance of warrant liabilities in conjunction with NSC debt 634 0
Beneficial conversion feature related to Opus Credit Facility 1,881 0
Acquisition of National    
Goodwill (21,739) 0
Accounts receivable (4,889) 0
Cash deposits with clearing organizations (1,030) 0
Receivables from broker-dealers and clearing organizations (1,607) 0
Securities owned, at fair value (2,178) 0
Prepaid expenses and other current assets (1,985) 0
Property and equipment, net (1,132) 0
Restricted cash (353) 0
Accounts payable and accrued expenses 6,079 0
Accrued commissions and payroll payable 14,029 0
Deferred clearing and marketing credits 1,007 0
Other current liabilities 707 0
Non-controlling interests 17,717 0
Net cash acquired in acquisition of National $ 4,626 $ 0